(198 days)
Silkn FX is an over the counter device indicated to emit energy in the red and IR region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.
Silk'n FX is a hand held device battery operated that uses low power light spectrum at red and infrared LED, at wavelength of 633 ±5nm, 830 ±5nm emitting optical power in a uniform distribution with no hot spots.
The provided 510(k) summary for the Silk'n FX device does not include any acceptance criteria or a study demonstrating the device meets such criteria.
Instead, the submission outlines the device's technical specifications and claims substantial equivalence to a predicate device based on identical output and intended use. The FDA's letter concurs with this substantial equivalence.
Therefore, most of the requested information cannot be extracted from this document, as a detailed performance study with acceptance criteria was not presented as part of this particular FDA submission for the Silk'n FX.
Here's what can be stated based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance:
Not provided in the document. The submission claims substantial equivalence based on identical output and intended use to a predicate device, rather than meeting specific performance criteria.
2. Sample size used for the test set and data provenance:
Not applicable. No performance study data is presented.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
Not applicable. No performance study data is presented.
4. Adjudication method for the test set:
Not applicable. No performance study data is presented.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This device is an LED device for wrinkle treatment, not an AI-powered diagnostic tool. The submission does not mention any MRMC studies or human reader involvement.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable. This device is an LED device; there is no algorithm or AI component mentioned.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
Not applicable. No performance study data is presented.
8. The sample size for the training set:
Not applicable. No performance study data or machine learning component is mentioned.
9. How the ground truth for the training set was established:
Not applicable. No performance study data or machine learning component is mentioned.
{0}------------------------------------------------
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS Home Skinovations Ltd. Silk'n FX AUG 1 9 2011
(10301
This summary of safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.
Submitter's information
| Name: | Home Skinovations Ltd. |
|---|---|
| Address: | Tavor building, POB 533, Yokneam 20692, Israel |
| Contact: | Dr. Amir Waldman VP Regulatory Affairs |
Device information
| Trade/Proprietary name: | Silk'n FX |
|---|---|
| Common/Usual name: | Light Emitting Diode (LED) device |
| Classification name: | Laser surgical instrument for use in general and plasticsurgery and in dermatology (21CRF §878.4810) |
| Product code: | OHS |
Predicate device
- . Omnilux New-U, (K072459), By Photo Therapeutics Inc.
Intended use:
Silkn FX is an over the counter device indicated to emit energy in the red and IR region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.
Device Description:
Silk'n FX is a hand held device battery operated that uses low power light spectrum at red and infrared LED, at wavelength of 633 ±5nm, 830 ±5nm emitting optical power in a uniform distribution with no hot spots.
Performance data:
The device complies with the following U.S. Food and Drug Administration performance standards: 21CRF § 1040.10 & 1040.11.
{1}------------------------------------------------
Substantial Equivalence:
The Silk'n FX is substantial equivalent to its predicate device. The data in this 510(k) submission demonstrate that the Silk'n FX device has identical output and intended use as other predicate device. Therefore is substantial equivalent to its predicate devices.
Based upon an analysis of the overall performance characteristic for the device, Home Skinovations Ltd. believes that no significant differences exit. Therefore the Silk'n FX should raise no new issues of safety or effectiveness.
January 27, 2011
Date
Amir Vahdat
Dr. Amir Waldman, VP Regulatory Affairs Home Skinovations Ltd.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle faces right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Home Skinovations Ltd. % Amir Waldman, Ph.D. Tavor Building, P.O.Box 533 Yokneam 20692, Israel
AUG 1 9 2011
Re: K110301
Trade/Device Name: Silk'n FX Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: OHS Dated: August 14, 2011 Received: August 17, 2011
Dear Dr. Waldman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
{3}------------------------------------------------
Page 2 – Amir Waldman, Ph.D.
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Madeline Millman
Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
11 030 1 510(k) Number (if known)_
Device Name Silk'n FX
Indications For Use:
Silkn FX is an over the counter device indicated to emit energy in the red and IR region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over The Counter Use_X
(Optional Format 1-2-96)
Nilke Qyde for mkn
(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K110301
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.